Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Bio-IT World Conference.
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED
Bio-IT World Conference — 2026 — Boston, USA
The 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville. The conference will be a day of concurrent paper sessions and a keynote presentation. We welcome p
3,000+ Attendees
6 Presentations
3 Companies
2 Drugs
Presentation data updated Jun 13, 2026, 9:34 PM UTC
Why This Event Matters
The 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville.
Industry impact
The 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to oncology markets in the US region.
Regulatory implications
Trial readouts and FDA/EMA label-expansion discussions drive near-term catalysts for oncology investors attending this congress.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Bio-IT World Conference.
Competitive implications
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
67 /100 composite
Bio-IT World Conference ranks among the highest-impact gatherings on our calendar for oncology — where partnership timing, regulatory narrative, and investor catalysts converge. Primary driver: downstream media and analyst follow-through.
- Media coverage 20/20
High follow-on media and sell-side note volume expected within 24–48h of key sessions.
- Speaker quality 20/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 1/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 20/20
Prior editions moved stock prices and label expansions — expect similar volatility windows.
- Company participation 6/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Watch session: Long-term readout from the phase 3 RUBY trial (NCT03981796) in endometrial cancer
- Johnson & Johnson carries 1 tracked presentations — map against peer readouts at Bio-IT World Conference.
- National Cancer Institute carries 2 tracked presentations — map against peer readouts at Bio-IT World Conference.
- Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Bio-IT World Conference.
- Trial readouts and FDA/EMA label-expansion discussions drive near-term catalysts for oncology investors attending this congress.
- amivantamab (Johnson & Johnson) — 1 data points on the schedule.
Timeline & Milestones
- Pre-event intelligence Complete
6 presentations tracked — Key Data and Companies hubs live.
- Conference opens May 15, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
4 Nova articles linked — see Coverage & Analysis.
- Conference closes May 17, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Oncology BD teams Clinical development leaders Investors & analysts
Executive Summary
C-level briefThe 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville.
Primary audience: Oncology BD teams · Clinical development leaders · Investors & analysts
Analyst Watch
Regulatory affairs
Trial readouts and FDA/EMA label-expansion discussions drive near-term catalysts for oncology investors attending this congress.
Competitive intelligence
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Most Anticipated Presentations
Full data hub → PRESENTATION
Long-term readout from the phase 3 RUBY trial (NCT03981796) in endometrial cancer
PRESENTATION
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk
PRESENTATION
Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463)
ORAL May 15
Navigating the Data Landscape: The Cancer Research Data Commons Data Ecosystem
PRESENTATION
Results for SSGJ-707 (PD-1/VEGF bispecific antibody) in non-small cell lung cancer
POSTER
AI Enablement Across CRDC and CCDI
Competitive Landscape
Company map →Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Drug Pipelines to Watch
Pipeline data →Related Clinical Trials
2 NCT IDs- NCT03981796 Long-term readout from the phase 3 RUBY trial (NCT03981796) in endometrial cance
- NCT04077463 Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463)
Coverage & Analysis
3 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for Bio-IT World Conference — optimized for research and AI retrieval.
Executive Summary
The 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville.
Analyst View
The 2026 Federal Statistical Research Data Center (FSRDC) Annual Research Conference will be taking place on Friday, September 18, 2026, at the University of Florida in Gainesville.
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Bio-IT World Conference.
BD View
BD teams should prioritize networking with presenting companies and services vendors at Bio-IT World Conference, focusing on oncology partnership and licensing opportunities.
Key Facts
- Event
- Bio-IT World Conference
- Focus
- oncology
- Region
- US Americas
- Attendance
- 3,000+
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is Bio-IT World Conference?
Bio-IT World Conference is a oncology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends Bio-IT World Conference?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on oncology.
Why is Bio-IT World Conference important?
Bio-IT World Conference influences partnership timing, pipeline prioritization, and policy debates that affect oncology markets for the next 12–18 months.
When is Bio-IT World Conference?
Bio-IT World Conference takes place on the scheduled dates.
Where is Bio-IT World Conference held?
Bio-IT World Conference is held in the listed venue.
How many attendees does Bio-IT World Conference attract?
Bio-IT World Conference typically draws 3,000+ attendees from across the oncology ecosystem.
What companies participate at Bio-IT World Conference?
3+ companies present data or participate in programming at Bio-IT World Conference, spanning large pharma, biotech, and services vendors.
What should investors watch at Bio-IT World Conference?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on oncology catalysts during and after Bio-IT World Conference.
What BD opportunities exist at Bio-IT World Conference?
BD teams use Bio-IT World Conference for licensing discussions, co-development talks, and vendor selection across oncology — especially in networking sessions and satellite meetings.
How does Bio-IT World Conference compare with other pharma conferences?
Bio-IT World Conference is a tier-1 global congress for oncology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of Bio-IT World Conference?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for Bio-IT World Conference. Subscribe to event alerts on this page for breaking updates.